Novo Nordisk Warns of First Sales Drop Since Start of Ozempic
The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry and faces lower prices for its medicines under a deal with President Trump.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
